Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention (Q34645876)

3 August 2017

1 reference

title

Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention (English)

1 reference

generalized anxiety disorder

3 August 2017

1 reference

1 reference

Borwin Bandelow

1

1 reference

3 August 2017

Dirk Wedekind

series ordinal

2

1 reference

3 August 2017

Teresa Leon

series ordinal

3

1 reference

3 August 2017

publication date

1 July 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

3 August 2017

published in

1 reference

3 August 2017

volume

7

1 reference

3 August 2017

issue

7

1 reference

3 August 2017

page(s)

769-781

1 reference

Generalized anxiety disorder: prevalence, burden, and cost to society.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

The epidemiology of generalized anxiety disorder in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Comorbidity in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Factors predicting the clinical course of generalised anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

A review and meta-analysis of the genetic epidemiology of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Escitalopram in the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Evidence-based pharmacotherapy of Generalized Anxiety Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Activity profile of pregabalin in rodent models of epilepsy and ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Pharmacokinetics of pregabalin in subjects with various degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Pregabalin in generalized anxiety disorder: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

Accounting for dropout bias using mixed-effects models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.7.769

21 January 2018

Identifiers

DOI

10.1586/14737175.7.7.769

1 reference

3 August 2017

1 reference